TG Therapeutics ranked first on Deloitte Technology Fast 500 due to significant growth from BRIUMVI MS treatment revenues.

Quiver AI Summary

TG Therapeutics, Inc. announced it has been ranked as the fastest-growing company in North America on the Deloitte Technology Fast 500 list, which recognizes the top 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies. This achievement is attributed to the company's growth from 2020 to 2023, primarily driven by the sales of its multiple sclerosis treatment, BRIUMVI, approved in December 2022. CEO Michael S. Weiss emphasized the company's commitment to developing treatment options for those with relapsing forms of multiple sclerosis and expressed gratitude for the support from the community. The Deloitte Technology Fast 500 recognizes companies based on revenue growth percentage, requiring a minimum revenue threshold and a proprietary technology contribution to operating revenues.

Potential Positives

• TG Therapeutics ranked number one on the Deloitte Technology Fast 500, highlighting its status as the fastest-growing company in North America.
• The company's growth was primarily driven by the successful launch and revenue generation of BRIUMVI, which was approved by the FDA in December 2022 for the treatment of relapsing forms of multiple sclerosis.
• The recognition reflects the commitment and effort of TG Therapeutics' team in developing effective treatment alternatives for patients in need.

Potential Negatives

• Even though TG Therapeutics ranks number one on the Deloitte Technology Fast 500, this recognition could highlight potential volatility if the growth is unsustainable or driven mainly by a single product, BRIUMVI, which may pose risks if market conditions change.
• The significant reliance on BRIUMVI for revenue raises concerns about the company's ability to diversify its portfolio, making it vulnerable if the product's acceptance or sales encounter obstacles.
• Warnings about serious side effects, including infections and severe infusion reactions associated with BRIUMVI, may impact physician and patient acceptance, potentially hindering sales growth.

FAQ

What is TG Therapeutics' recent achievement?

TG Therapeutics ranked number one on the Deloitte Technology Fast 500 list for fastest-growing companies in North America.

What is BRIUMVI and its indication?

BRIUMVI is a monoclonal antibody approved to treat adults with relapsing forms of multiple sclerosis (RMS).

How did TG Therapeutics achieve its growth?

The growth was primarily driven by revenues from BRIUMVI, since its approval in December 2022.

What is the Deloitte Technology Fast 500?

The Deloitte Technology Fast 500 ranks the 500 fastest-growing technology and life sciences companies in North America.

Who is the CEO of TG Therapeutics?

Michael S. Weiss is the Chairman and Chief Executive Officer of TG Therapeutics.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$TGTX Insider Trading Activity

$TGTX insiders have traded $TGTX stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here's a breakdown of recent trading of $TGTX stock by insiders over the last 6 months:

• SAGAR LONIAL has traded it 3 times. They made 0 purchases and 3 sales, selling 30,933 shares.
• LAURENCE N CHARNEY sold 25,000 shares.
• YANN ECHELARD sold 20,000 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$TGTX Hedge Fund Activity

We have seen 187 institutional investors add shares of $TGTX stock to their portfolio, and 131 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• BLACKROCK, INC. added 10,567,851 shares (+92.8%) to their portfolio in Q3 2024
• STATE STREET CORP added 2,398,015 shares (+35.8%) to their portfolio in Q3 2024
• MARSHALL WACE, LLP removed 2,051,762 shares (-100.0%) from their portfolio in Q3 2024
• CITADEL ADVISORS LLC removed 1,734,658 shares (-93.3%) from their portfolio in Q3 2024
• VANGUARD GROUP INC added 1,695,600 shares (+12.4%) to their portfolio in Q3 2024
• SOFINNOVA INVESTMENTS, INC. removed 1,502,633 shares (-80.7%) from their portfolio in Q3 2024
• MILLENNIUM MANAGEMENT LLC removed 1,446,114 shares (-99.2%) from their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX),


today announced it ranked number one on the

Deloitte Technology Fast 500

, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30

th

year.

The Company's growth between fiscal years 2020 to 2023 was fueled by BRIUMVI revenues, which was approved to treat adult individuals with relapsing forms of multiple sclerosis in December of 2022.

Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "We are proud to be recognized as the fastest-growing company in North America on the Deloitte Technology Fast 500 list. This recognition reflects the unwavering commitment of our incredible team and the strong success in bringing BRIUMVI to people with relapsing forms of multiple sclerosis. As we continue our mission to develop and provide treatment alternatives for those in need, we are grateful for the trust and support we have received from the multiple sclerosis community."

About the 2024 Deloitte Technology Fast 500

Now in its 30

th

year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Deloitte

Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500 and more than 8,500 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an

impact that matters

by creating trust and confidence in a more equitable society. We leverage our unique blend of business acumen, command of technology, and strategic technology alliances to advise our clients across industries as they

build their future

. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte's approximately 460,000 people worldwide connect for impact at



.

ABOUT TG THERAPEUTICS

TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit



, and follow us on X (formerly Twitter)

@TGTherapeutics

and on

LinkedIn

.

BRIUMVI is a registered trademark of TG Therapeutics, Inc.

ABOUT BRIUMVI (ublituximab-xiiy) 150 mg/6 mL Injection for IV

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.

BRIUMVI is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

A list of authorized specialty distributors can be found at




.

IMPORTANT SAFETY INFORMATION

Contraindications: BRIUMVI is contraindicated in patients with:

• 
  Active Hepatitis B Virus infection
  
• 
  A history of life-threatening infusion reaction to BRIUMVI
  

WARNINGS AND PRECAUTIONS

Infusion Reactions:

BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization.

Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.

Infections:

Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI-treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved.

Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.

Hepatitis B Virus (HBV) Reactivation:


HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HBsAg and anti-HB tests. For patients who are negative for surface premedantigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.

Progressive Multifocal Leukoencephalopathy (PML):


Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies.

If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.

If PML is confirmed, treatment with BRIUMVI should be discontinued.

Vaccinations:


Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.

Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy:


In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19

+

B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.

Fetal Risk:

Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is recommended in females of reproductive potential prior to each infusion. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.

Reduction in Immunoglobulins:

As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

Most Common Adverse Reactions:

The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections.

Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit



.

ABOUT BRIUMVI PATIENT SUPPORT

BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at



.

ABOUT MULTIPLE SCLEROSIS

Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately 85% are initially diagnosed with RRMS.

1,2

The majority of people who are diagnosed with RRMS will eventually transition to SPMS, in which they experience steadily worsening disability over time. Worldwide, more than 2.3 million people have a diagnosis of MS.

1

ABOUT TG THERAPEUTICS

TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit



, and follow us on X (formerly Twitter)

@TGTherapeutics

and on

LinkedIn

.

BRIUMVI is a registered trademark of TG Therapeutics, Inc.

Cautionary Statement

This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.

Such forward looking statements include but are not limited to statements regarding expectations for the commercial launch of BRIUMVI (ublituximab-xiiy) for RMS in the United States; and anticipated healthcare professional (HCP) and patient acceptance and use of BRIUMVI for the approved indications.

Additional factors that could cause our actual results to differ materially include the following: the Company's ability to continue to maintain a commercial infrastructure for BRIUMVI, and to successfully market and sell BRIUMVI; the risk that the Company's BRIUMVI U.S. net revenue targets will not be achieved; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements, the potential for variation from the Company's projections and estimates about the potential market for BRIUMVI due to a number of factors, including, further limitations that regulators may impose on the required labeling for BRIUMVI (such as modifications, resulting from safety signals that arise in the post-marketing setting or in the long-term extension study from the ULTIMATE I and II clinical trials); the Company's ability to meet post-approval compliance obligations (on topics including but not limited to product quality, product distribution and supply chain, pharmacovigilance, and sales and marketing); the Company's reliance on third parties for manufacturing, distribution and supply, and other support functions for its clinical and commercial products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; and general political, economic and business conditions. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in our other filings with the SEC.

Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at



. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

CONTACT:

Investor Relations:

Email:

ir@tgtxinc.com

Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:

Email:

media@tgtxinc.com

Telephone: 1.877.575.TGTX (8489), Option 6

1.



MS Prevalence. National Multiple Sclerosis Society website.







. Accessed October 26, 2020.



2.



Multiple Sclerosis International Federation, 2013 via


Datamonitor


p. 236.